Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis

Xiao-nan ZHANG; Yan-yang LI; Yuan-hui ZHANG; Wan-qin ZHANG; Ya-ping ZHU; Jun-ping ZHANG; Shi-chao LV; Long-tao LIU

doi:10.1007/s11655-022-2884-5

Your Location：

Home >

Browse articles >

Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis

Evidence-Based Integrative Medicine | Updated：2022-03-29

- Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis
- Chinese Journal of Integrative Medicine Vol. 28, Issue 4, Pages: 374-383(2022)
- Affiliations：
  
  1.National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
  2.Tianjin Medical University Cancer Institute and Hospital, Tianjin (300060), China
  3.First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin (300112), China
- Author bio：
  
  Prof. LIU Long-tao, E-mail: liulongtao1976@126.com
- Funds：
- DOI：10.1007/s11655-022-2884-5
  CLC：
- Published：2022-04，
  
  Accepted：13 September 2021
Scan for full text
Xiao-nan ZHANG, Yan-yang LI, Yuan-hui ZHANG, et al. Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis. [J]. Chinese Journal of Integrative Medicine 28(4):374-383(2022)
DOI：

Xiao-nan ZHANG, Yan-yang LI, Yuan-hui ZHANG, et al. Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis. [J]. Chinese Journal of Integrative Medicine 28(4):374-383(2022) DOI： 10.1007/s11655-022-2884-5.

摘要

目的:

系统评价生脉散治疗蒽环类药物心脏毒性患者的疗效.

方法:

通过检索自建库至2020年12月中国知网 (CNKI) 、万方、中国生物医学文献数据库 (CBM) 、PubMed、Cochrane Library和 Embase 数据库的随机对照试验 (RCTs)

采用Cochrane 手册评估纳入研究的偏倚风险

RevMan 5.3软件进行Meta分析.

结果:

共纳入19项RCTs

2331 名参与者

结果显示

在改善心律失常方面(13 RCTs

n=1877

RR=0.37

95% CI 0.25 to 0.52

0.00001)

治疗组优于对照组; 在减小左心室舒张末期内径 (LVEDD

2 RCTs

=128

MD=–0.79

95% CI –0.93 to –0.65

0.00001) 和左心室收缩末期内径 (LVESD

2 RCTs

=128

MD=–0.58

95% CI –0.82 to –0.35

0.00001)

治疗组同样优于对照组; 在降低心肌酶方面如肌酸激酶 (CK) [(3 RCTs

=256

SMD=–0.80

95% CI –1.16 to –0.44

0.0001)

(2 RCTs

=126

SMD=– 0.62

95% CI –0.98 to –0.26

=0.0007)]

治疗组优于对照组.

结论:

生脉散对蒽环类药物心脏毒性的治疗具有积极作用

但未来仍需开展高质量的RCTs来验证其疗效.

Abstract

Objective:

To systematically evaluate the efficacy of Shengmai San in patients with cardiotoxicity of anthracyclines.

Methods:

Randomized controlled trials (RCTs) were identified by searching China National Knowledge Infrastructure (CNKI)

Wanfang Database

Chinese Biomedical Literature Database (CBM)

PubMed

Cochrane Library

and Embase Databases from the inceptions until December 2020. The Cochrane Handbook was used to evaluate the risk of bias in the included studies. Data analysis was conducted using RevMan 5.3 software.

Results:

Totally 19 RCTs with 2

331 participants were included in this review. Results showed that in improving arrhythmia (13 RCTs

877

RR=0.37

95% CI 0.25 to 0.52

0.00001)

the treatment group was superior to the control group. In terms of reducing left ventricular end-diastolic diameter (LVEDD

2 RCTs

=128

MD=–0.79

95% CI –0.93 to –0.65

0.00001) and left ventricular end systolic diameter (LVESD

2 RCTs

=128

MD=–0.58

95% CI –0.82 to –0.35

0.00001)

the treatment group was also better than the control group. In reducing myocardial enzymes such as creatine kinase (CK) [(3 RCTs

=256

SMD=–0.80

95% CI –1.16 to –0.44

0.0001)

(2 RCTs

=126

SMD=–0.62

95% CI –0.98 to –0.26

=0.0007)]

the treatment group was superior to the control group.

Conclusion:

Shengmai San has a positive effect on the treatment of cardiotoxicity from anthracyclines. However

in the future

it is still necessary to conduct high-quality RCTs to verify its efficacy.

关键词

Keywords

Shengmai Sananthracyclinescardiotoxicitysystematic reviewmeta-analysis

references

Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938-945.

Ma J, Qin SK, Shen ZX. Guidelines for the prevention and treatment of cardiotoxicity of anthracyclines (2013 edition).J Clin Oncol (Chin) 2013;18:925-934.

Patane S. Cardiotoxicity: anthracyclines and long term cancer survivors. Int J Cardiol 2014;176:1326-1328.

Chung WB, Youn HJ. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med 2016;31:625-633.

Cruz M, Duarte-Rodrigues J, Campelo M. Cardiotoxicity in anthracycline therapy: Prevention strategies. Rev Port Cardiol 2016;35:359-371.

Seif A E, Walker DM, Li Y, et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer 2015;62:704-709.

Li WT, Yu BY, Wu MH. Zhou Zhongying's experience in treating postoperative lung cancer patients from the view of qi and yin deficiency. J Tradit Chin Med (Chin) 2016;57:643-645.

Cao P, Zheng GY, Ruan Y, Yao M, Yue XQ. Professor Ling Chang-quan's experience in treating malignant tumor based"cancer toxicity" theory. Chin J Integr Tradit Chin West Med(Chin) 2020;40:1-4.

Li YY, Sun HY, Jiang ZS, et al. Research on the prevention and treatment of cardiac toxicity of antitumor drugs in traditional Chinese medicine. J Basic Chin Med (Chin)2018;24:1602-1606.

Hao W, Liu S. Research progress on prevention of anthracycline-induced cardiotoxicty by Chinese medicine.Shanghai J Tradit Chin Med (Chin) 2016;50:99-102.

Chen YF, Yu RY, Xiong YK, et al. Application and mechanism of traditional Chinese medicine in preventing and treatment of adriamycin-induced cardiotoxicity. Chin J Exp Tradit Med Form (Chin) 2018;24:207-217

Zhang JH, Wu CJ, Cai G, et al. Systematic evaluation of Shenmai Injection for prevention and treatment of cardiotoxicity induced by chemotherapy of malignant tumor.Chin J Inf Tradit Chin Med (Chin) 2018;25:96-100.

Wang Y. Study on the protective effect of Shengmai Yin combined with benazepril on cardiac function in patients with chronic heart failure induced by tumor drugs. J Cardiovasc Cerebrovasc Dis Integr Tradit Chin West Med(Chin) 2018;16:1156-1160.

Huang YF. Evaluation of the effect of combined treatment of dexrazoxane and Shenmai Injection on reducing cardiotoxicity in chemotherapy of acute leukemia. Cardiovasc Dis Electronic J Integr Traditi Chin West Med (Chin) 2018;6:156158.

Fang GY, Zhang QM, Wei AQ, et al. Shenmai combined with dexrazoxane in the prevention and treatment of cardiotoxicity in 31 patients with breast cancer caused by anthracycline. Chin J Critical Care Med (electronic edition, Chin) 2017;10:406-407.

LV ZH, Jiang SQ. Influence of combined treatment of dexrazoxane and Shenmai Injection on reducing cardiotoxicity in the acute leukemia chemotherapy. J Tropical Med (Chin) 2017;17:633-636.

Wang YL, Li JL, Yan ZH, et al. Evaluation of the efficacy of Shenmai Injection in improving the cardiac side effects of drugs. Chin Pract Med (Chin) 2017;12:123-125.

Yu W, Guo ZQ, Xie RX, et al. Clinical observation of the reduction of anthracycline-induced cardiotoxicity in patients with breast cancer by dexrazoxane combined with Shenmai Injection. Chin Pharm (Chin) 2015;26:4562-4564.

Liu Q, Zhang XF, Cheng XF, et al. Clinical observation of cardiac toxicity induced by FAC regimen in female breast cancer treated by Shenmai Injection. Acta Chin Med (Chin)2014;29:1090-1091,1094.

Li QY, Zhu LM, Li YB, et al. Protective effect of Shenmai Injection for cardiac muscle of breast cancer patients during pirarubicin chemotherapy. Youjiang Med J (Chin)2014;42:669-671.

Ma FC. Effect of Shenmai Injection on myocardial enzyme level in patients with malignant tumor receiving epirubicin chemotherapy. J Basic Clin Oncol (Chin) 2014;27:66-67.

Su YW. Clinical observation of Shenmai Injection in the prevention and treatment of cardiotoxicity of epirubicin.World Late Med (electronic version, Chin) 2013;5:189-190.

Ge Y, Hu XL, Hao DS, et al. Cardioprotective effect of Shenmai Injection on chemotherapy in patients with acute leukemia. World Health Digest (Chin) 2013;33:70.

Wang CY, Song CY, Shen FM. Study on the protective effect of Shenmai Injection on cardiotoxicity of doxorubicin.Clin Focus (Chin) 2012;27:1169-1170.

Zhang J. Myocardial protective effect of Shengmai Injection on doxorubicin chemotherapy in patients with malignant tumor. Guangming J Chin Med (Chin) 2011;26:530.

Yang XL, Zhang H, Hou YM. Myocardium protective effects of Shenmai Injection to Xinjiang women with breast cancer subject to 5-fluorouracil chemotherapy. J Clin Cardiol (Chin)2011;27:138-141.

Chen HL. Observation of Shenmai Injection in preventing cardiotoxicity of anthracycline chemotherapeutic drugs.Zhejiang J Tradit Chin Med (Chin) 2009;12:928

Li Q, Zhang WJ, Ma QZ, et al. Electrocardiographic observation of Shenmai Injection in the treatment of cardiotoxicity induced by doxorubicin. Mili Med J South Chin (Chin) 2008;10:43-45.

Yang XL. Clinical observation on the prevention of doxorubicin-associated cardiotoxicity by Shengmai Injection. Guide Chin Med (Chin) 2008;6:203-205.

Wang RQ, Xie Y, Zhao SZ. Clinical observation of Shengmai Injection in the prevention and treatment of cardiotoxicity induced by doxorubicin. Chin J Int Med Cardio-Cerebrovasc Dis (Chin) 2006;4:1092-1093.

Xiong P, Lian J, Yu XQ. An electrocardiogram analysis in 83 galactophore cancer patients in ADM chemotherapy.Proc Clin Med (Chin) 2006;15:263-264.

Sala V, Sala AD, Hirsch E, et al. Signaling pathways underlying anthracycline cardiotoxicity. Antioxid Redox Signal 2020;32:1098-1114.

Rocca C, Pasqua T, Cerra MC, et al. Cardiac damage in anthracyclines therapy: Focus on oxidative stress and inflammation. Antioxid Redox Signal 2020;32:1081-1097.

Cao ZH, Pan JH, Li N, et al. Modern pharmacological effect and mechanism of Shengmai San. Chin J Exp Tradit Med Form (Chin) 2019;25:212-218.

Zhou YL, You K. Two cases report of old people chronic heart failure treated by Shengmai Powder. J Pract Tradit Chin Intern Med (Chin) 2016;30:77-79.

Geng Y, Xu HY, Ma YX, et al. Composition principles of formula containing Shengmai San in dictionary of Chinese medicine prescription. Chin J Exp Tradit Med Form (Chin)2017;23:200-205.

Geng Y, Ma YX, Xu HY, et al. Drug Standards of the Ministry of Health of the People's Republic of China–Prescriptions of Chinese Medicines: An analysis of the prescription rules of Chinese patent medicines containing Shengmai San.Liaoning J Tradit Chin Med (Chin) 2017;44:1018-1021.

Wang HE, Bai WY, Liu Z, et al. Research progress of Shengmai prescription. Chin Tradit Patent Med (Chin) 2019;41:151-159.

Liu LK, Song W, Hao SL, et al. Reversal effect of Shengmai Injection containing serum on multidrug resistant human gastric cancer cell and its possible mechanism. China J Tradit Chin Med Pharm (Chin) 2018;33:4204-4208.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effectiveness and Safety of Chinese Medicine at Shenque (CV 8) for Primary Dysmenorrhea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Related Author

No data

Related Institution

China Academy of Chinese Medical Sciences

College of Preschool Education, Beijing Youth Politics College

School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine

School of Acupuncture and Moxibustion, Tianjin University of Traditional Chinese Medicine

Primary Care and Population Sciences, Faculty of Medicine, University of Southampton

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰